Ironwood Pharmaceuticals (NASDAQ:IRWD) Posts Quarterly Earnings Results, Beats Estimates By $0.15 EPS

Ironwood Pharmaceuticals (NASDAQ:IRWD) announced its quarterly earnings results on Monday. The biotechnology company reported $0.24 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.15, Zacks reports. Ironwood Pharmaceuticals had a negative return on equity of 2.46% and a negative net margin of 2.25%.The company had revenue of $122.06 million during the quarter, compared to analyst estimates of $74.22 million. Ironwood Pharmaceuticals updated its FY 2025 guidance to EPS.

Ironwood Pharmaceuticals Price Performance

Shares of Ironwood Pharmaceuticals stock traded up $0.23 during trading on Wednesday, reaching $3.12. 1,474,083 shares of the stock traded hands, compared to its average volume of 2,556,941. Ironwood Pharmaceuticals has a 52-week low of $0.53 and a 52-week high of $5.13. The business has a fifty day simple moving average of $1.54 and a two-hundred day simple moving average of $1.07. The company has a market capitalization of $506.79 million, a price-to-earnings ratio of -62.37 and a beta of 0.37.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. AQR Capital Management LLC grew its position in Ironwood Pharmaceuticals by 535.8% during the 1st quarter. AQR Capital Management LLC now owns 2,523,875 shares of the biotechnology company’s stock worth $3,710,000 after purchasing an additional 2,126,889 shares during the last quarter. Millennium Management LLC lifted its stake in shares of Ironwood Pharmaceuticals by 186.6% during the first quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company’s stock worth $9,349,000 after buying an additional 4,140,439 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Ironwood Pharmaceuticals during the first quarter worth $57,000. Goldman Sachs Group Inc. grew its holdings in shares of Ironwood Pharmaceuticals by 72.1% during the first quarter. Goldman Sachs Group Inc. now owns 1,575,416 shares of the biotechnology company’s stock valued at $2,316,000 after buying an additional 660,144 shares during the last quarter. Finally, Jane Street Group LLC grew its holdings in shares of Ironwood Pharmaceuticals by 740.5% during the first quarter. Jane Street Group LLC now owns 3,510,117 shares of the biotechnology company’s stock valued at $5,160,000 after buying an additional 3,092,475 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Wall Street Zen upgraded Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 9th. Wells Fargo & Company raised their price objective on shares of Ironwood Pharmaceuticals from $1.00 to $3.00 and gave the stock an “equal weight” rating in a report on Tuesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ironwood Pharmaceuticals in a report on Wednesday, October 8th. Finally, Zacks Research downgraded shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. One equities research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $5.34.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.